Concepedia

Author

I Popov

Oncology Institute of VojvodinaORCID

Also Known As

I POPOV, I Popov, I. P. Popov, I. Popov, Ivan P. Popov, Ivan Popov, Popov, Ivan

94

Publications

588

Citations

13

H-Index

26

Concepts

All Affiliations

Oncology Institute of VojvodinaMécanismes physiopathologiques et conséquences des calcifications cardiovasculairesLaurentius ZiekenhuisHospital General Universitario de ElcheUniversité de Picardie Jules Verne
IP

About

I Popov is an author at Oncology Institute of Vojvodina specializing in medicine, pharmacotherapy, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

196

2

Health Sciences

1

1

49

3

Anesthesia

1

1

46

4

Endocrinology

1

1

11

5

Gastroenterology

1

1

15

I Popov

×

13

Publications

459

Citations

12

H-Index

YearCitations

Combinations of Serum Prostate-Specific Antigen and Plasma Expression Levels of let-7c, miR-30c, miR-141, and miR-375 as Potential Better Diagnostic Biomarkers for Prostate Cancer

Darina Kachakova, A. Mitkova, Elenko Popov,

DNA and Cell Biology

2014

108

Preterm labour--is bacterial vaginosis involved?

H J Odendaal, I Popov, J. C. Schoeman,

PubMed

2002

70

Raltitrexed (Tomudex®) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)

I Popov, Alfredo Carrato, Alberto Sobrero,

European Journal of Cancer

2008

49

Reversal of neuromuscular blockade by sugammadex in laparoscopic bariatric surgery: In support of dose reduction

R. Badaoui, A. Cabaret, Youssef Alami,

Anaesthesia Critical Care & Pain Medicine

2015

46

Outpatient laparoscopic sleeve gastrectomy: first 100 cases

R. Badaoui, Youssef Alami Chentoufi, Abdelhakim Hchikat,

Journal of Clinical Anesthesia

2016

37

Tumor markers in metastatic disease from cancer of unknown primary origin.

Marijana Milović-Kovačević, I Popov, Svietislav Jelić

PubMed

2002

35

Chemoembolization for liver metastases from colorectal carcinoma: risk or a benefit.

I Popov, Slobodan Lavrnić, S. Jelić,

PubMed

2002

21

Irinotecan as Second-Line Treatment in Metastatic Colorectal Cancer: Dilemmas Regarding Patient Selection and Toxicity Prediction

Z. Nikolić-Tomašević, S. Jelić, I Popov,

Journal of Chemotherapy

2000

19

A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: The Pan-European Trial in Adjuvant Colon Cancer 2 study

Claus‐Henning Köhne, Laurent Bedenne, Alfredo Carrato,

European Journal of Cancer

2013

17

Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study

S. Jelić, Nada Babović, Vladimir Kovčin,

Melanoma Research

2002

17

Page 1